Last reviewed · How we verify
Allogeneic Mesenchymal Stromal Cell — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Allogeneic Mesenchymal Stromal Cell (Allogeneic Mesenchymal Stromal Cell) — Martin Teraa, MD, PhD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allogeneic Mesenchymal Stromal Cell TARGET | Allogeneic Mesenchymal Stromal Cell | Martin Teraa, MD, PhD | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allogeneic Mesenchymal Stromal Cell CI watch — RSS
- Allogeneic Mesenchymal Stromal Cell CI watch — Atom
- Allogeneic Mesenchymal Stromal Cell CI watch — JSON
- Allogeneic Mesenchymal Stromal Cell alone — RSS
Cite this brief
Drug Landscape (2026). Allogeneic Mesenchymal Stromal Cell — Competitive Intelligence Brief. https://druglandscape.com/ci/allogeneic-mesenchymal-stromal-cell. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab